The development of a side effect risk assessment tool (ASyMS©-SERAT) for use in patients with breast cancer undergoing adjuvant chemotherapy

Roma Maguire (Lead / Corresponding author), Julie Cowie, Clare Leadbetter, Kathryn McCall, Kevin Swingler, Lisa McCann, Nora Kearney

    Research output: Contribution to journalArticle

    11 Citations (Scopus)

    Abstract

    Patients with breast cancer receiving chemotherapy are at risk of developing toxicities which can be severe or life threatening. The aim of this study was to develop and test a side effect risk modeling tool (ASyMS -SERAT) for use in patients with breast cancer undergoing adjuvant chemotherapy. The study was conducted in two phases. Phase 1 entailed the development of the ASyMS-SERAT tool using a secondary data set and in collaboration with an expert group of clinicians and an advisory group of patients. In phase 2, the predictive accuracy of the tool was measured using a prospective data set of 24 patients with breast cancer undergoing adjuvant chemotherapy. A high level of accuracy was reported for four of the six symptoms measured (>70%) supporting the future development and application of ASyMS-SERAT in the prediction of chemotherapy-related toxicity. For patients, such information can be used to target information on side effects that they are likely to experience thereby facilitating the provision of tailored information based on their individual needs. For clinicians, knowing the likelihood of potential side effects can assist them in identifying patients who are at greater risk of developing certain toxicities, facilitating more targeted and cost-effective interventions. © 2009 Sage Publications.
    Original languageEnglish
    Pages (from-to)27-40
    Number of pages14
    JournalJournal of Research in Nursing
    Volume14
    Issue number1
    DOIs
    Publication statusPublished - 2009

    Keywords

    • Breast cancer
    • Chemotherapy

    Fingerprint Dive into the research topics of 'The development of a side effect risk assessment tool (ASyMS©-SERAT) for use in patients with breast cancer undergoing adjuvant chemotherapy'. Together they form a unique fingerprint.

  • Cite this